2025年3月30日 · ST6GAL1 (ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 1) is a Protein Coding gene. Diseases associated with ST6GAL1 include Colon Adenocarcinoma and Puerperal Pulmonary Embolism. Among its related pathways are Early SARS-CoV-2 Infection Events and superpathway of glycosphingolipids biosynthesis.

Beta-galactoside alpha-2,6-sialyltransferase 1 is an enzyme that in humans is encoded by the ST6GAL1 gene. [5] The protein encoded by this gene is a type II membrane protein that catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates.

编码的蛋白质是一种 II 型膜蛋白，可催化唾液酸从 CMP-唾液酸转移到含半乳糖的底物。 这种蛋白质通常存在于高尔基体中，但可以通过蛋白水解加工成可溶性形式，参与细胞表面碳水化合物决定簇和分化抗原 HB-6、CD75 和 CD76 的生成。 该基因被错误地称为 CD75。 可变剪接导致多个转录本变体。 [RefSeq 提供，2017 年 7 月] This gene encodes a member of …

2022年12月17日 · Using a metabolic labeling-based glycoproteomic strategy, we identified a list of sialylated proteins that may be regulated by ST6GAL1. In particular, an increase in α2,6 sialylation of melanoma...

ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. ST6GAL1 and alpha2-6 Sialylation Regulates IL-6 Expression and Secretion in Chronic Obstructive Pulmonary Disease. ST6GAL1 polymorphisms influence susceptibility and progression of IgA nephropathy in a Chinese Han population.

2025年2月8日 · Title: N-linked α2,6-sialylation of integrin β1 by the sialyltransferase ST6Gal1 promotes cell proliferation and stemness in gestational trophoblastic disease. ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression.

2022年8月28日 · ST6Gal1 adds sialic acid to the terminal galactose of N-glycoproteins in an α2,6 bond in the trans-Golgi (Figure 1). This α2,6 sialylation by ST6Gal1 is not only a prognostic marker for select cancers but also a driver of malignant progression (Munkley and Elliott, 2016).

ST6GAL1 catalyses the addition of α2,6-linked sialic acids to terminal N-glycans and can modify glycoproteins and/or glycolipids. ST6GAL1 is upregulated in numerous types of cancer (including pancreatic, prostate, breast and ovarian cancer) and can …

利用糖生物学，蛋白组学技术，分子生物学及细胞生物学技术，在体外细胞模型及动物模型中发现st6gal1通过影响icam-1的稳定性调控crc转移。同时，在临床样本中评估其与患者预后的相关性。从细胞、动物、临床三个方面揭示唾液酸修饰在crc转移过程中的机制。

已在多种癌症中观察到β-半乳糖苷α2,6-唾液酸转移酶1（st6gal1）的表达升高。但是，st6gal1如何影响癌细胞的机制仍有待阐明。我们以前的研究通过质谱分析（ms）将细胞间粘附分子1（icam-1）识别为st6gal1的可能底物。icam-1与多种癌症中的肿瘤转移有关。